The OPTIONS Study is looking at how well a study drug works for adults with relapsing-remitting multiple sclerosis (RRMS) who are currently experiencing a relapse and have not benefited from high-dose corticosteroid treatment.
About 66 adults from across the United States will take part in this study. The study will last for about 13 weeks and will involve up to 5 visits to the study center, as well as 1 telephone call.
Would you like to take part?
You may be able to take part in the OPTIONS Study if you:
- are at least 18 years of age
- have a diagnosis of RRMS
- are currently experiencing a relapse
- start treatment for the relapse within 28 days of the first signs of the relapse.
All study medication and assessments will be provided at no cost to you.
If you are interested in taking part, please call us as soon as possible when you start experiencing a relapse.
To learn more about this study, please contact the study team today.
You can also find a description of the study by visiting www.clinicaltrials.gov and searching for MNK14274069 or NCT03126760.
Contact: Valerie Carvajal (Valerie.Carvajal@mnk.com)
